Metformin as an Upstream Therapy in Atrial Fibrillation

Atrial Fibrillation Clinical Trial

Official title: Metformin as an Upstream Therapy in Atrial Fibrillation

Status Terminated

Clinical Trial Summary

The purpose of this study is to see if the study drug metformin will help patients who are overweight and have atrial fibrillation. This study aims to see if metformin helps patients stay in normal sinus rhythm after a catheter ablation.

Metformin is investigational for use in patients with atrial fibrillation. Metformin is approved by the Food and Drug Administration (FDA) for use in patients with type 2 Diabetes Mellitus. Metformin is used with a proper diet and exercise program to control high blood sugar, and has been shown to help people lose weight. This study aims to look at the effects of metformin on weight loss and heart rhythm in patients with atrial fibrillation.

Clinical Trial Description

Enrollment: Consent, medical history, and dietary education. Randomization. treatment Metformin 500mg daily and increased as tolerated to 2000 mg daily over three weeks or control -no treatment. 6 weeks. Pre procedure safety labs, EKG, Atrial Fibrillation Severity Score survey, metformin held 48 hours prior to rhythm control procedure. Treatment resumed 48 hours post procedure or when renal function at baseline. Treatment plan for 6 months or discontinuation at any time they are found to meet the baseline exclusion criteria. Follow-up at 3 month and 6 month post procedure. Continuation of treatment at study completion determined by primary cardiologist or care provider. ;

Related Conditions & MeSH terms

• Atrial Fibrillation

• NCT number: NCT02931253
• Study type: Interventional
• Source: The Guthrie Clinic
• Status: Terminated
• Phase: Phase 2
• Start date: April 11, 2017
• Completion date: July 10, 2018